Literature DB >> 28235523

Fast-track anesthesia in patients undergoing outpatient laparoscopic cholecystectomy: comparison of sevoflurane with total intravenous anesthesia.

Ceyda Özhan Çaparlar1, Mehmet Özgür Özhan2, Mehmet Anıl Süzer3, Dilek Yazicioğlu1, Mehmet Burak Eşkin4, Serkan Şenkal5, Mehmet Ali Çaparlar6, Ersin Özkan Imren7, Bülent Atik8, Nedim Çekmen9.   

Abstract

BACKGROUND: The use of short-acting anesthetics has introduced a "fast-track anesthesia" concept in outpatient surgery which provides discharge of the patients from operation room directly to the phase II recovery area without entering into postanesthesia care unit. The aim of this prospective and randomized study was to compare general anesthesia using sevoflurane with propofol-remifentanil-based total intravenous anesthesia (TIVA) for fast-track eligibility in patients undergoing outpatient laparoscopic cholecystectomy. The secondary aim was to compare 2 discharge scoring systems: White's Fast-Tracking Scoring System (WFTSS) and Modified Aldrete Scoring Systems (MASS) with regard to postanesthesia care unit bypass rate and postoperative problems.
METHODS: After obtaining ethical approval and written informed patient consent, 80 patients were randomly assigned into 2 groups: group sevoflurane (n=40) and group TIVA (n=40). Anesthesia was induced with propofol, fentanyl, and rocuronium in both groups and maintained with sevoflurane in group sevoflurane and with remifentanil-propofol in group TIVA. Fast-track eligibility was evaluated using both WFTSS and MASS while patients were discharged from operation room according to WFTSS. Recovery times, number of fast-track eligible patients, factors related to fast-track ineligibility, and perioperative complications were evaluated.
RESULTS: The ratio of fast-track eligible patients was higher and times to fast-track eligibility were shorter in group TIVA compared with group sevoflurane (82.1% vs 57.5% and 8 minutes vs 12 minutes; P<.05). The primary factors that have inhibited fast-tracking were desaturation, hemodynamic instability, pain, and postoperative nausea and vomiting, respectively. Postoperative nausea and vomiting presented a major difference in the rate of fast-track ineligibility between groups (4 patients in group sevoflurane, whereas none in group TIVA; P<.05). The fast-track ratio was lower with the WFTSS compared with MASS in group sevoflurane (57.5% vs 77.5%, P<.05), but similar in group TIVA.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28235523     DOI: 10.1016/j.jclinane.2016.10.036

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  4 in total

1.  Preemptive Nalbuphine Attenuates Remifentanil-Induced Postoperative Hyperalgesia After Laparoscopic Cholecystectomy: A Prospective Randomized Double-Blind Clinical Trial.

Authors:  Jun Hu; Shuangshuang Chen; Mudan Zhu; Yun Wu; Ping Wang; Jinbao Chen; Ye Zhang
Journal:  J Pain Res       Date:  2020-07-28       Impact factor: 3.133

2.  Sevoflurane may be more beneficial than propofol in patients receiving endoscopic variceal ligation and endoscopic variceal sclerotherapy: A randomized, double-blind study.

Authors:  Linghua Tang; Huimin Liu; Yang Wu; Mei Li; Wei Li; Meng Jiang; Jiabao Hou; Ying Jiang; Zhongyuan Xia; Qingtao Meng
Journal:  Exp Ther Med       Date:  2017-08-09       Impact factor: 2.447

3.  Esmolol does not improve quality of postsurgical recovery after ambulatory hysteroscopy: A prospective, randomized, double-blinded, placebo-controlled, clinical trial.

Authors:  Gildasio S De Oliveira; Mark C Kendall; Robert J McCarthy
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

4.  Anesthesia Effect of Remifentanil Combined with Propofol in Laparoscopic Cholecystectomy and Its Impact on Postoperative Cognitive Recovery.

Authors:  Wei Jiang; Jun Wang; Xin-Xin Ni; Zu-Chao Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-15       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.